§ 26B-4-243 — Guidance for treatment with medical cannabis.

The department, in consultation with the Center for Medical Cannabis Research created in Section 53H-4-206, shall:
(1) develop evidence-based guidance for treatment with medical cannabis based on the latest medical research that shall include:
(1)(a) for each qualifying condition, a summary of the latest medical research regarding the treatment of the qualifying condition with medical cannabis;
(1)(b) risks, contraindications, side effects, and adverse reactions that are associated with medical cannabis use; and
(1)(c) potential drug interactions between medical cannabis and medications that have been approved by the United States Food and Drug Administration;
(2) educate recommending medical providers, pharmacy medical providers, medical cannabis cardholders, and the public regarding:
(2)(a) the evidence-based guidance for treatment with medical cannabis described in Subsection (1)(a);
(2)(b) relevant warnings and safety information related to medical cannabis use; and
(2)(c) other topics related to medical cannabis use as determined by the department; and
(3) develop patient product information inserts for medical cannabis products:
(3)(a) in consultation with the cannabis processing facility that created the product; and
(3)(b) that do not contain proprietary information about the product.

Legislative History

Amended by Chapter 9, 2025 Special Session 1